Ligand Pharm (LGND)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 06-2023 | 03-2023 | 12-2022 | 09-2022 | 06-2022 | |
| Sales | 26,366 | 43,979 | 50,382 | 59,221 | 50,126 |
| Cost of Goods | 1,669 | 3,717 | 21,614 | 14,153 | 12,361 |
| Gross Profit | 24,697 | 40,262 | 28,768 | 45,068 | 37,765 |
| Operating Expenses | 27,349 | 26,774 | 49,481 | 32,880 | 29,464 |
| Operating Income | -1,983 | 14,205 | -20,099 | 12,341 | 8,662 |
| Interest Expense | 284 | 240 | 240 | 332 | 438 |
| Other Income | 5,438 | 41,571 | 44,479 | 345 | 437 |
| Pre-tax Income | 3,171 | 55,536 | 24,140 | 12,354 | 8,661 |
| Income Tax | 881 | 11,922 | 38,674 | 2,709 | -3,938 |
| Net Income Continuous | 2,290 | 43,614 | -14,534 | 9,645 | 12,599 |
| Net Income Discontinuous | N/A | -1,665 | -2,951 | -9,241 | -13,494 |
| Net Income | $2,290 | $41,949 | $-17,485 | $404 | $-895 |
| EPS Basic Total Ops | 0.13 | 2.46 | -1.04 | 0.02 | -0.05 |
| EPS Basic Continuous Ops | 0.13 | 2.56 | -0.86 | 0.57 | 0.75 |
| EPS Basic Discontinuous Ops | N/A | -0.10 | -0.17 | -0.55 | -0.80 |
| EPS Diluted Total Ops | 0.13 | 2.33 | -1.04 | 0.02 | -0.05 |
| EPS Diluted Continuous Ops | 0.13 | 2.43 | -0.84 | 0.56 | 0.74 |
| EPS Diluted Discontinuous Ops | N/A | -0.09 | -0.19 | -0.54 | -0.79 |
| EBITDA(a) | $6,764 | $23,138 | $-8,765 | $26,015 | $21,917 |